Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with sever...Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.展开更多
目的探究乌司他丁联合维生素D对重症哮喘合并呼吸衰竭患者的影响。方法选取120例重症哮喘合并呼吸衰竭患者作为研究对象,随机分为对照组和观察组,每组60例。对照组予以常规治疗,观察组在对照组治疗的基础上予以乌司他丁联合维生素D治疗...目的探究乌司他丁联合维生素D对重症哮喘合并呼吸衰竭患者的影响。方法选取120例重症哮喘合并呼吸衰竭患者作为研究对象,随机分为对照组和观察组,每组60例。对照组予以常规治疗,观察组在对照组治疗的基础上予以乌司他丁联合维生素D治疗。比较2组的预后恢复情况、血清炎症因子[高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、白细胞介素-8(interleukin-8,IL-8)、白细胞介素-17(interleukin-17,IL-17)]、氧化应激反应[超氧化物歧化酶(superoxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)]、肺功能[第1秒用力呼气容积占预计值的百分比(percentage of forced expiratory volume in first second to the expected value,FEV_(1)%)、第1秒用力呼气容积占用力肺活量的比值(the ratio of forced expiratory volume in first second to forced vital capacity,FEV_(1)/FVC)、最大呼气峰流速(peak expiratory flow,PEF)]及不良反应的发生情况。结果治疗后,相较于对照组,观察组咳嗽持续时间、气促持续时间及住院时间均明显缩短(P<0.05);血清hs-CRP、IL-8和IL-17水平均明显降低(P<0.05);血清SOD水平明显升高,MDA水平明显降低(P<0.05);FEV_(1)%、FEV_(1)/FVC、PEF均明显升高(P<0.05);观察组的不良反应总发生率明显低于对照组(P<0.05)。结论乌司他丁联合维生素D可缓解患者的临床症状,缩短住院时间,下调血清炎症因子水平,抑制氧化应激反应,改善肺功能。展开更多
文摘Objective:This study aims to evaluate the clinical efficacy of non-invasive positive pressure ventilation(NIPPV)in patients with severe bronchial asthma combined with respiratory failure.Methods:90 patients with severe bronchial asthma combined with respiratory failure between September 2022 and December 2023 were selected for the study and randomly divided into the experimental group(NIPPV-assisted treatment)and the control group.The differences between the two groups were compared in terms of total effective rate of treatment,days of clinical symptom disappearance,days of hospitalization,lung function indexes,incidence of adverse reactions,and quality of life.Results:Patients in the experimental group had a significantly higher total effective rate of treatment(97.78%)than the control group(75.56%).In terms of pulmonary function indexes,patients in the experimental group showed significant improvement after treatment,especially the increase in forced expiratory volume and forced vital capacity,while these improvements were not as obvious in the control group.In addition,the incidence of adverse reactions was significantly lower in the experimental group than in the control group,suggesting that the application of NIPPV is relatively safe.Quality of life assessment also showed that patients in the experimental group had significantly better quality of life than the control group after treatment.Conclusion:This study demonstrated the effectiveness of NIPPV as an adjunctive treatment for severe bronchial asthma combined with respiratory failure.NIPPV can improve lung function,reduce the incidence of adverse effects,increase the overall effectiveness of the treatment,and contribute to the improvement of patients'quality of life.Therefore,NIPPV should be regarded as an effective and safe treatment in clinical management,especially in patients with severe bronchial asthma combined with respiratory failure,where its application has potential clinical significance.
文摘目的探究乌司他丁联合维生素D对重症哮喘合并呼吸衰竭患者的影响。方法选取120例重症哮喘合并呼吸衰竭患者作为研究对象,随机分为对照组和观察组,每组60例。对照组予以常规治疗,观察组在对照组治疗的基础上予以乌司他丁联合维生素D治疗。比较2组的预后恢复情况、血清炎症因子[高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、白细胞介素-8(interleukin-8,IL-8)、白细胞介素-17(interleukin-17,IL-17)]、氧化应激反应[超氧化物歧化酶(superoxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)]、肺功能[第1秒用力呼气容积占预计值的百分比(percentage of forced expiratory volume in first second to the expected value,FEV_(1)%)、第1秒用力呼气容积占用力肺活量的比值(the ratio of forced expiratory volume in first second to forced vital capacity,FEV_(1)/FVC)、最大呼气峰流速(peak expiratory flow,PEF)]及不良反应的发生情况。结果治疗后,相较于对照组,观察组咳嗽持续时间、气促持续时间及住院时间均明显缩短(P<0.05);血清hs-CRP、IL-8和IL-17水平均明显降低(P<0.05);血清SOD水平明显升高,MDA水平明显降低(P<0.05);FEV_(1)%、FEV_(1)/FVC、PEF均明显升高(P<0.05);观察组的不良反应总发生率明显低于对照组(P<0.05)。结论乌司他丁联合维生素D可缓解患者的临床症状,缩短住院时间,下调血清炎症因子水平,抑制氧化应激反应,改善肺功能。
